We determined fluoxetine (Prozac#{174}) and its major metabolite norfluoxetine in plasma by liquid chromatography with fluorescence detection. After liquid-liquid extraction from 1 mL of plasma, the extract was denvatized at room temperature with dansyl chloride, and the highly fluorescent derivatives were chromatographed with a reversedphase C15 column and a mobile phase of phosphate buffer and acetonitrile. Dansylated fluoxetine, norfluoxetme, and the internal standard were eluted in <14 mm with no interference from endogenous material. The calibration curve was linear over the concentration range 25-800 tg/L with inter-and intra-assay imprecision (CV) of <10%. Validity of the assay was checked by comparing results for 110 patients' samples with those by a liquidchromatographic method with ultraviolet detection (r = 0.993 for fluoxetine, 0.957 for norfluoxetine). The identity of the dansylated derivatives was verified by positive chemical ionization mass spectroscopy. The lower limit of detection was -3 g/L. Because no major antidepressant, neuroleptic, or respective drug metabolites interfere with the quantificationof fluoxetine and noriluoxetine, this is a useful procedure for pharmacokinetic studies and in clinical settings.
ChromatographicConditions
The mobile phase consisted of an isocratic mixture of 250 mL of 0.025 mol/L monobasic potassium phosphate and 750 mL of acetonitrile per liter with 500 L of o-phosphoric acid and 600 pL of n-butylamine added. This was pumped through a 25 x 0.46 cm column packed with 5-jm particles of octadecyldimethylsilyl (Supelcosil LC-18; Supelco, Bellefonte, PA 16823). A flow rate of 2.0 mL/min resulted in a back pressure of 9.660-11.040 MPa, depending on the age of the column. The mobile phase was filtered and degassed daily before use. The excitation wavelength of the fluorescence detector was set at 235 nm, and a 470-nm cutoff filter (emission wavelength) was used to monitor fluorescence. The detector signal response time was set at 1 s and the attenuation of 0.04 pA full scale adequately captured most steady-state concentrations of FLX and NFLX. The signal output to the data-acquisition system was amplified through an analog-to-digital converter (Model DCI 2000; Perkin-Elmer Corp., Norwalk, CT 06859). All quantifications were performed by calculating peakheight ratios of FLX and NFLX to the internal standard. The data system performed a least-squares linear-regression analysis for each of the calibration curves. The excitation and emission wavelengths for dansylated FLX, NFLX, and maprotiline were optimized according to a previous assay that also used dansylated maprotiline as an internal standard for a TCA analysis (14). Excitation at 235 nm and a cutoff filter at 470 rim afforded the greatest sensitivity under our analytical conditions. Decreasing the excitation wavelength to 
Table 2. Recovery of Fluoxetine and Norfluoxetlne
Concentration added, pg/I. a Percent recovered (and CV, %) from 1 mLat plasma n = 10 for each concentration.
<235mm did not increase the signal/noise ratio. Using a light source other than deuterium (e.g., xenon) would require re-opt mi7lng these wavelengths.
The precision of this method was determined by supplementing 11 1-mL aliquota of drug-free plasma with various amounts of FLX and NFLX. After addition pf the internal standard, the samples were processed as described, together with a standard calibration curve. The average result for each added concentration and the respective CVs are listed in Table 1 . The determination of the low concentration (3 pgfL) was carried out with use of a scaled-down calibration curve containing FLXJ NFLX at 150 to 3 pg/L and a 50 &g/L internal standard. Day-to-day variability was assessedby analyzing quality-control samples with each batth of patients' samples. The quality-control samples were prepared at 150 and 600 ig/L and stored frozen at -20 #{176}C. The respective day-to-day variations (CVs) were 7.5% and 5.5% for FLX and 8.1% and 9.9% for NFLX (n = 22 consecutive days). An additional daily inspection of the calibration curve parameters, specifically the linear-regression slope, gave another measure of day-to-day consistency.
The absolute recovery of the drugs from plasma was determined by preparing an aqueous solution of known concentrations of FLX and NFLX. The internal standard was added to each solution, the solutions were derivatized, and portions were injected into the chromatograph. The same standards were added to 1 mL of plslmnR and processed routinely except that the internal standard, 200 ng of maprotiline, was added to the final acid extract and derivatized as previously deathbed. The difference between the ratio of standards to internal standard in processed samples vs the direct-injection samples indicated the overall extraction recovery ( other commonly used ring-nitrogen-containing TCAs (e.g., imipramine, desipramine) displayed natural fluorescence and, therefore, still interfered. DNS-Cl has been widely used as a label for preparing fluorescent conjugates of proteins and for specific amino acids. Because DNS-Cl reacts readily with primary and secondary amines in alkaline buffer, it is generally regarded as the derivatizing reagent of choice in preparing highly fluorescent compounds, enhancing the sensitivity and selectivity of drugs and metabolites ( (as assayed by a gas-chromatographlc method) matograms essentially because of the high content of acetonitrile in the mobile phase, so that most underivatized compounds were eluted at the solvent front. Furthermore, this high ratio of organic to aqueous solvent in the mobile phase also served to lengthen the column lifetime and allow lower operating back-pressure. Table 3 lists 25 commonly used extracted and derivatized psychiatric drugs and metabolites with their retention times. Except for several drugs as-yet unapproved for use in the US and m-chlorophenylpiperazine (a metabolite of trazodone), the commonlyprescribed antidepressants do not elute with FLX, NFLX, or the internal standard. This is demonstrated in Figure 2 , chromatograms of two patients' plasma samples that contained both FLX and desipramine or ELX and nortriptyline. An additional 26 drugs and metabolites tested were either not dansylated, not extracted, or eluted with the solvent front. In general, compounds with no primary or secondary amine function did not interfere.
To assess the validity of this assay (x), we compared results for 110 plasimfi samples previously analyzed for FLX and NFLX by a slightly modified method (y) for TCA analyses (16 All of the samples used for comparisons were free of these and other possible interfering drugs, and all were re-analyzed within 8 months of the original analyses, having been stored frozen at -20#{176}C in the interim. 
